We have received non-dilutive funding from various regional, national and European grants, including ERDF.
LIQOSEAL®
Polyganics and partners received funding from the European Fund for Regional Development (ERDF) by the European Union, through the Northern Netherlands Alliance (SNN) and from the city and province of Groningen to support the clinical validation of LIQOSEAL® More.
Research directed at the use of LIQOSEAL® for adjacent indications is currently supported with a KEI (“Kennis en Innovatie”) grant.
ACTISEAL®
The clinical validation of ACTISEAL® is being supported with funding from the European Fund for Regional Development (EFRO) through the Northern Netherlands Alliance (SNN) and the city and province of Groningen. More
Drug Eluting Medical Devices
Polyganics is exploring opportunities to incorporate active pharmaceutical ingredients (APIs) into its devices. Effective delivery of these components to the surgical area has the potential to facilitate and/or accelerate wound healing and patient recovery. Research in this field is being supported with funding from the European Fund for Regional Development (EFRO) through the Northern Netherlands Alliance (SNN).
New facility
Polyganics realized a new facility at Zernike Campus, Groningen, which housing its headquarters, state-of-the-art research laboratories and expanded manufacturing and packaging facilities. Polyganics has been awarded a subsidy of €3.8 million by the Regional Investment Aid Groningen (RIG) initiative to support this development. More
